65156-92-5

Basic information

• Product Name: Ethenamine, N,N-dimethyl-2-(3-nitro-2-pyridinyl)-
• CAS NO: 65156-92-5
• Molecular Formula: C9H11N3O2
• Molecular Weight: 193.205
• Mol File: 65156-92-5.mol
• Article Data: 12

Chemical Properties

• CAS DataBase Reference: Ethenamine, N,N-dimethyl-2-(3-nitro-2-pyridinyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Ethenamine, N,N-dimethyl-2-(3-nitro-2-pyridinyl)-(65156-92-5)
• EPA Substance Registry System: Ethenamine, N,N-dimethyl-2-(3-nitro-2-pyridinyl)-(65156-92-5)

Safety Data

• Hazardous Substances Data: 65156-92-5(Hazardous Substances Data)

Upstream product

• 18699-87-1 2-methyl-3-nitropyridine 
• 1188-33-6 N,N-dimethylformamide diethyl diacetal 
• 173417-34-0 dimethyl 2-(3-nitropyridin-2-yl)malonate 
• 5470-18-8 2-Chloro-3-nitropyridine 
• 142078-31-7 2-methyl-3-nitro-6-styrylpyridine 
• 15513-52-7 3-nitro-2,6-lutidine 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 64362-41-0 diethyl 2-(3-nitropyridin-2-yl)malonate 

Downstream Products

• 272-49-1 1H-pyrrolo[3,2-b]pyridine 
• 1312545-23-5 3-(4-azaindol-3-yl)-4-(3,4,5-trimethoxyphenyl)-1H-pyrrol-2,5-dione 
• 143621-35-6 3-aminopyridine-2-carboxaldehyde thiosemicarbazone 
• 36625-67-9 3-nitropyridine-2-carboxaldehyde thiosemicarbazone 
• 10261-94-6 3-nitropyridine-2-carboxaldehyde 

Relevant articles and documents

BICYCLIC DIAMINES AS JANUS KINASE INHIBITORS

The instant invention provides compounds of formula I which are Jak inhibitors, and as such are useful for the treatment of Jak-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.

Novel 3-azaindolyl-4-arylmaleimides exhibiting potent antiangiogenic efficacy, protein kinase inhibition, and antiproliferative activity

Tumor growth and metastasis are highly associated with the overexpression of protein kinases (PKs) regulating cell growth, apoptosis resistance, and prolonged cell survival. This study describes novel azaindolyl-maleimides with significant inhibition of PKs, such as VEGFR, FLT-3, and GSK-3β which are related to carcinogenesis. Furthermore, these compounds exhibit high kinase selectivity and potent inhibition of angiogenesis and cell proliferation, offering versatile options in cancer treatment strategies.

3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarcinoma

The present invention relates to the use of a compound of formula (I) wherein R1, and R3 are as defined in the description and R2 is a phenyl group which is substituted with 2 or 3 C1-G6 alkoxy groups, or a physiologically acceptable salt thereof, or a solvate of the compound of formula (I) or of the salt thereof, for treatment of colorectal or gastric adenocarcinoma.